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Abstract
Low serum 25 hydroxyvitamin D3  (vitamin D3) is known to perturb cellular function in many
tissues, including the endocrine pancreas, which are involved in obesity and type II diabetes mellitus
(TIIDM). Vitamin D3 insufficiency has been linked to obesity, whether obesity is assessed by body
mass index (BMI) or waist circumference (waist). Central obesity, using waist as the surrogate, is
associated with the metabolic syndrome (MetSyn), insulin resistance, TIIDM and atherosclerotic
cardiovascular disease (CVD). We tested how vitamin D3  was related to measures of fat mass,
MetSyn markers, haemoglobin A1c  (HbA1c) and MetSyn in a cross-sectional sample of 250
overweight and obese adults of different ethnicities. There were modest inverse associations of
vitamin D3  with body weight (weight) (r = -0.21, p = 0.0009), BMI (r = -0.18, p = 0.005), waist (r
= -0.14, p = 0.03), [but not body fat % (r = -0.08, p = 0.24)], and HbA1c  (r = -0.16, p = 0.01).
Multivariable regression carried out separately for BMI and waist showed a decrease of 0.74 nmol/
L (p = 0.002) in vitamin D3  per 1 kg/m2  increase in BMI and a decrease of 0.29 nmol/L (p = 0.01)
per 1 cm increase in waist, with each explaining approximately 3% of the variation in vitamin D3
over and above gender, age, ethnicity and season.
The similar relationships of BMI and waist with vitamin D3  may have been due to associations
between BMI and waist, or coincidental, where different mechanisms relating hypovitaminosis D3
to obesity occur concurrently. Previously reviewed mechanisms include that 1) low vitamin D3, may
impair insulin action, glucose metabolism and various other metabolic processes in adipose and lean
tissue 2) fat soluble-vitamin D3  is sequestered in the large adipose compartment, and low in serum,
3) obese people may be sensitive about their body shape, minimising their skin exposure to view
and sunlight (not tested). We showed evidence for the first theory but no evidence to support the
second.
In the current study, serum vitamin D3  was inversely related to weight, BMI and markers of TIIDM
(large waist, raised HbA1c) but not to adipose mass nor to MetSyn per se.
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Background
It is now known that insufficient serum 25 hydroxyvita-
min D3 (calcifediol, vitamin D3) alters metabolite func-
tion causing perturbation of many cellular functions,
including that of the endocrine pancreas [1]. Recently,
there has been a resurgence of hypovitaminosis D3 in
many populations [2], including young, pale-skinned
adults [3] in addition to those with pigmented skin. Sug-
gested recent recommendations of ideal vitamin D3 serum
levels for metabolic health are >70–100 nmol/L (previ-
ously >50 nmol/L) [4,5]. In parallel, there has been a
world-wide increase in the prevalence of obesity [6]. Links
between hypovitaminosis D3  and obesity have been
reported when obesity is defined using body mass index
(BMI) [7,8] and waist circumference (waist) [9]. Large
waist, a surrogate for abdominal obesity, is the key marker
required for the metabolic syndrome (MetSyn) as defined
by the International Diabetes Federation (IDF) [10].
Whilst there is overlap in total body and abdominal obes-
ity, the diverse metabolic processes of different adipose
depots and lean tissue may underpin dissimilar hypothe-
ses for the mechanisms proposed for the inverse relation-
ship of vitamin D3 and obesity.
This study was designed to 1) assess the relationships
between vitamin D3 and anthropometric, metabolic syn-
drome and TIIDM markers, 2) determine whether whole
body [BMI] or central [waist] adiposity was significantly
related to vitamin D3, and if so whether one was related
independently of the other when corrected for well-
known influences in mixed-ethnicity adults.
Methods
Population and anthropometry
250 ambulant adults in Auckland, New Zealand were
recruited into a body weight (weight) loss trial with pri-
mary criteria including BMI 28–50 kg/m2, age >18 y, not
currently using weight loss agents nor participating in
commercial weight loss programmes, and a desire to lose
weight. Baseline data from this study were analysed for
relationships with vitamin D3. Ethnicity was the surrogate
for skin pigment. The lightly pigmented skin sub-group
consisted of Caucasians and the variably pigmented skin
sub-group included all other ethnicities which were New
Zealand Maori, Pacific Peoples (Tongan, Samoan,) and
Asian (East, South or Indian). For anthropometry, partic-
ipants were lightly clad and measurements were taken in
duplicate. Weight, height, waist and blood pressure were
measured using standard methods as detailed in our pre-
vious publication [11]. Body fat percentage (fat%) was
assessed indirectly by multi-frequency bioelectrical
impedance analysis (SFB3 MFBIA, Impedimed, Australia).
All participants provided written informed consent. Ethics
approval for this study was obtained from the Auckland
Ethics Committee, Auckland, New Zealand.
Laboratory samples
Participants attended our community clinic for collection
of fasting blood. 200 women and 43 men provided eval-
uable samples. Vitamin D3 was analysed using Vit D25
pre-extraction with acetonitrile, double antibody radioim-
munoassay (DiaSorin Inc Stillwater, MN, USA). Fasting
plasma glucose (FPG), serum lipids and haemoglobin A1c
(HbA1c) were measured using standard methods [11].
Statistical Analysis
Linear regression analysis was used to investigate the rela-
tionships of the demographic data, anthropometry and
laboratory tests with vitamin D3. Multivariable regression
was performed with vitamin D3 as the outcome variable.
Explanatory variables were gender, age, ethnicity, season,
and either BMI or waist as these were likely to be highly
correlated. An analysis including both BMI and waist was
also carried out to investigate if one variable contributed
over and above the other. SAS 8.0 statistical software
(Cary, NC, 2003) was employed for analyses.
Results
Baseline data shows an obese population with preva-
lences of MetSyn and TIIDM ≈ 40% and 5% in 234 partic-
ipants with available FPG. Table 1.
There were modest but significant inverse relationships of
vitamin D3 with weight (p = 0.0009), BMI (p = 0.005) and
waist (p = 0.03) but no relationship could be shown with
fat %. Figure 1. Vitamin D3 could not be shown to be
related to any of the non-waist MetSyn markers (Met-
SynM) or MetSynMcount (number of markers added
together) or the presence of MetSyn (p > 0.05, all). Vita-
min D3 and HbA1c, alone of the individual metabolic and
MetSynM were weakly inversely related (p = 0.01) but this
relationship was not significant after exclusion of the
three HbA1c values >10% (p = 0.22). Abnormal FPG was
related to hypovitaminosis D3, again only when the three
values >10 mmol/L were included (r2 = 0.17, p = 0.005).
Figure 1.
Multivariable regression showed an estimated decrease of
0.74 nmol/L (p = 0.002) in vitamin D3 per 1 kg/m2
increase in BMI with the total model explaining 22% of
the variation in vitamin D3 levels and BMI explaining 3%
of the variation. On replacing BMI with waist, there was a
decrease of 0.29 nmol/L (p = 0.01) vitamin D3 per 1 cm
increase in waist, with the total model explaining 21% of
the variation in vitamin D3 and waist explaining 3%.
When both BMI and waist were included neither could be
demonstrated to contribute over and above the other (p =
0.25 and 0.67 respectively), nor could an association of
vitamin D3 with gender (p = 0.52) or age (p = 0.52) be
shown. However there was strong evidence of its associa-
tion with ethnicity (p < 0.0001) and season (p < 0.0001).Nutrition Journal 2008, 7:4 http://www.nutritionj.com/content/7/1/4
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Discussion
In the current study we showed that low levels of circulat-
ing vitamin D3 were inversely related to markers of TIIDM
(large waist and raised HbA1c), rather than total adipose
mass, non-waist MetSynM or MetSyn per se.
Of the three anthropometric variables that were signifi-
cantly inversely correlated with vitamin D3 only BMI and
waist were further investigated as weight is considered too
crude a measure of obesity. Vitamin D3 showed inverse
relationships separately, but of the same magnitude, with
both BMI and waist when corrected for confounders. Nei-
ther could be shown to be related to vitamin D3 given the
level of the other. This may indicate either similar mecha-
nisms, or that different metabolic processes are occurring,
coincidentally producing similar outcomes.
Hypotheses from the literature are discussed in light of our 
findings
Whole body obesity, as defined by BMI, has been associ-
ated with or contributes to low vitamin D3 status [8,12].
Wortsman et al., found lower vitamin D3 in the serum of
obese participants after experimental UV irradiation,
deducing that "obesity-associated vitamin D insufficiency
is likely due to the decreased bioavailability of vitamin D3
from cutaneous and dietary sources because of its deposi-
tion in body fat compartments" [12]. It was unclear from
that trial which fat compartments were involved. In the
current study MFBIA fat% did not correlate with vitamin
D3, in contrast to that of Arunabh et al., [13] where DEXA
was performed in women, BMI<24 kg/m2. Total body fat
includes both peripheral adipose at the hip and thigh,
with beneficial metabolic effects in both women and men
[14], as well as less healthy upper body and central fat
depots [15]. The opposing effects of these adipose depots
could possibly weaken any correlation with vitamin D3.
Furthermore, the lack of relationship of fat% with vitamin
D3  may reflect influences of fat-free compartments of
bone, muscle [16] and abdominal organs (liver, kidney,
gut [17]).
The links between the metabolic syndrome and vitamin
D3 are not clear. In the present study, apart from waist,
none of MetSynM alone, MetSynMcount, nor the pres-
ence of MetSyn (defined by three of five positive markers
[9]), was correlated with vitamin D3. This lack of relation-
ship of vitamin D3 and MetSyn has been reported previ-
ously [18], and two studies of vitamin D3 in the morbidly
obese report conflicting relationships [19,20]. However,
in the large USA NHANES dataset Ford et al., found that
abdominal obesity as measured by waist alone, in addi-
tion to MetSyn, was related to low vitamin D3, notably
affecting mixed-ethnicity participants equally [21].
Conversion of vitamin D3 to its derivative 1,25 vitamin D3
is complex and involves other hormones. 1,25 vitamin
D3, via its receptor which is present in insulin-producing
beta-islet cells, is known to be a potent regulator of cell
proliferation and differentiation [22,23]. However, there
is evidence that low vitamin D3 itself is associated with
TIIDM irrespective of 1,25 vitamin D3 [8]. The inverse
relationship of vitamin D3 with high to extreme HbA1c
[24,25] and/or FPG [7,8] may indicate that it is the long-
term, severely abnormal (carbohydrate) metabolism of
TIIDM [7,26,27] and muscle insulin resistance [28], that
is associated with hypovitaminosis D3. HbA1c, a glycated
protein, is a predictor of 2-hour glucose in oral glucose
Table 1: Baseline data from 250 female and male overweight and 
obese participants
Parameter Evaluable N1 Mean(SD)
Age (y) 243 47.6(11.6)
Weight (kg) 243 97.3(18.2)
Height (cm) 243 166(8)
Body mass index (kg/m2) 243 35.4(5.2)
Body fat (%) 243 38.2(6.6)
2Waist (cm) 243 100.4(12.8)
2Systolic blood pressure (mmHg) 243 123(18)
2Diastolic blood pressure (mmHg) 243 70(10)
2Triglyceride (mmol/L) 243 1.56(0.82)
2High density lipoprotein-cholesterol 
(mmol/L)
243 1.33(0.34)
2Fasting plasma glucose (mmol/L) 234 5.32(1.38)
Haemoglobin A1c (%) 217 5.25(0.82)
2Metabolic syndrome marker count 234 2.4(1.1)
Vitamin D3nmol/L*
Total 243 62.2(22.7)
Women 200 62.4(21.9)
Men 43 61.7(26.3)
Skin pigment, light 206 64.8(22.0)
Skin pigment, variable 37 47.5(20.0)
Summer 141 68.7(21.9)
Winter 102 53.3(20.6)
2Metabolic syndrome, no 135 61.4(22.8)
2Metabolic syndrome, yes 99 63.8(22.4)
Non-type II diabetes mellitus 223 62.7(22.7)
Type II diabetes mellitus 11 55.5(20.1)
* Raw data in pair sets. See text for multivariable regression results. 
1Although anthropometry was collected on all 250 participants, data is 
only shown for 243, as evaluable serum samples for vitamin D3 analysis 
were available for this number (N) only. 6 samples were not obtained 
due to unsuccessful venepuncture and 1 sample was lost in transit to 
the laboratory. For the sub-groups some samples were not evaluable 
due to sample quality or loss. Sample number (N) is shown for each 
category. 2 Metabolic syndrome (N=234) is defined by the International 
Diabetes Federation as 1) Waist circumference: Europids and 
Undefined groups [such as Maori and Pacific Peoples] ≥ 94 cm (men), ≥ 
80 cm (women), Asian (based on a Chinese, Malay and Indian Asian 
population) ≥ 90 cm (men) and ≥ 80 cm (women). Waist must be 
included, plus two or more of 2) Systolic and diastolic blood pressure ≥ 
130/85 mmHg, 3) High density lipoprotein – cholesterol <1.03 mmol/L 
(<40 mg/dL) men, <1.29 mmol/L (<50 mg/dL) women 4) Triglyceride ≥ 
1.69 mmol/L (150 mg/dL) 5) Fasting plasma glucose ≥ 5.6 mmol/L (≥ 
100 mg/dL) and/or on treatment medication for the latter 4 conditions.Nutrition Journal 2008, 7:4 http://www.nutritionj.com/content/7/1/4
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tolerance testing, [29] an indicator of chronic hypergly-
caemia, protein glycation damage [30] and oxidative
stress [31]. Many new, profound and interacting mecha-
nisms link hypovitaminosis D with other correlates of the
metabolic syndrome, including renin regulation [1]. Vita-
min D-upregulated protein-1 reportedly modulates
endothelial oxidative stress, macrophage and smooth
muscle function, depending on the stage of atherosclero-
sis [32,33].
Limitations of the present study include the cross sec-
tional design where cause cannot be attributed. Lifestyle,
body shape sensitivity [34,35] or cultural reasons [36] for
precluding skin exposure to view, and ultraviolet light for
efficient vitamin D3 synthesis, may selectively affect obese
people but were not examined.
In the current study low serum vitamin D3 was inversely
related to weight and BMI, but not fat mass, and to mark-
ers indicative of TIIDM (large waist and raised HbA1c),
rather than MetSyn per se. The link between hypovitami-
nosis D3 and metabolic disorders, including obesity, Met-
Syn, TIIDM and CVD requires further investigation,
particularly for those most at risk of these combined con-
ditions.
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